Abstract | OBJECTIVE: MATERIALS AND METHODS: RESULTS: No meaningful regimen-related toxicities were documented. Donor chimerism of 90 to 100% was achieved on day 14 and thereafter. The patient is doing well, without any recurrence of hemolysis 6 months after transplant. Follow-up chimerism studies confirmed stable and functioning donor-type hematopoiesis. CONCLUSIONS: NST may become a safe and curative approach in patients with PNH. Further studies are needed to establish the role of NST for treatment of PNH.
|
Authors | K Suenaga, Y Kanda, H Niiya, K Nakai, T Saito, A Saito, M Ohnishi, T Takeuchi, R Tanosaki, A Makimoto, S Miyawaki, T Ohnishi, S Kanai, K Tobinai, Y Takaue, S Mineishi |
Journal | Experimental hematology
(Exp Hematol)
Vol. 29
Issue 5
Pg. 639-42
(May 2001)
ISSN: 0301-472X [Print] Netherlands |
PMID | 11376878
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antilymphocyte Serum
- Immunosuppressive Agents
- Cladribine
- Cyclosporine
- Busulfan
|
Topics |
- Antilymphocyte Serum
- Busulfan
- Cladribine
- Cyclosporine
(therapeutic use)
- Graft Survival
- Graft vs Host Disease
(prevention & control)
- Hematopoietic Stem Cell Transplantation
(methods)
- Hemoglobinuria, Paroxysmal
(therapy)
- Histocompatibility
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Male
- Middle Aged
- Transplantation Conditioning
- Transplantation, Homologous
|